老马,我家6月确诊肺腺,6月份正版帕唑帕尼 ct基本无变化 $ y, C# a. j/ L3 F) s 7月份易瑞沙 主灶基本无变化,胸膜转移灶增大( W4 }8 c& m( c7 h
8月份易瑞沙 主灶基本无变化,出现少量胸水 : n5 ?0 r# P j5 J( z' `7 C' J7 L& k 9~10月中药 ct主灶大了近一倍,胸水增多,右下肺部分压缩不张 7 `' K' ?8 |. t6 J y, u# M3 Q 11月份阿西替尼 ct胸水增多,几乎到胸腔一半的位置了, ' |; \& p' P# {, f# W5 R) Z2 L 其他与10月份ct无变化6 I5 }0 S s" D
现在吃了7天特, 咳嗽比较厉害- H9 H5 x2 B7 N8 m. X
如不吃特,请问老马有什么建议?
Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation; z8 ] r' ~- G3 H
Genomic characterization of recurrent breast and lung tumors developed over the course of 10 years in a 29-year-old patient with a germline p53 mutation (Li-Fraumeni Syndrome) identified oncogenic alterations in the HER2 and EGFR genes across all tumors, including HER2 amplifications, an EGFR-exon 20 insertion, and the first-in-human HER2-V659E mutation showing a phenotypic convergent evolution towards HER2 and EGFR alterations. Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy. A clinical response both symptomatic and radiologic was achieved. HER2-V659E sensitivity to lapatinib was confirmed in the laboratory.